IL-2 upgrades show promise at ASCO

IL-2 upgrades show promise at ASCO

-

Companies pursue souped-up IL-2 candidates, undeterred by Nektar’s setback.

Undeterred by bempegaldesleukin’s demise, the industry is forging ahead with a diverse pipeline of designer IL-2–based agents — more than a dozen of which are now in the clinic — as developers hope to overcome the challenges that have kept the cytokine from its immuno-oncology promise (Table 1). Many companies are eyeing applications in autoimmunity, too. “There are a lot of good strategies that are out there,” says Marc Ernstoff, chief of the ImmunoOncology Branch at the US National Cancer Institute. “Each of the engineered IL-2–like drugs is unique — and I think each will have to be tested.”

Table 1 IL-2 therapies in oncology trials

This is a preview of subscription content

Access options

Subscribe to Nature+

Get immediate online access to the entire Nature family of 50+ journals

Subscribe to Journal

Get full journal access for 1 year

$99.00

only $8.25 per issue

All prices are NET prices.

VAT will be added later in the checkout.

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Authors and Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. IL-2 upgrades show promise at ASCO.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01390-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-022-01390-3

Read More

Latest news

Intuitive Machines moves landing site of first mission to lunar south pole

WASHINGTON — Intuitive Machines is moving the landing site for its first lunar lander mission to the south polar...

SpaceX launches Hispasat’s Amazonas Nexus communications satellite

TAMPA, Fla. — SpaceX successfully launched the Amazonas Nexus telecoms satellite Feb. 6, which will fuel Spanish operator Hispasat’s...

Cash-rich EchoStar to take on global IoT market next year

TAMPA, Fla. — EchoStar Corporation, a U.S. operator with around $1.6 billion in cash, is preparing to disrupt the...

CACI to collaborate with U.S. Army on space technologies

WASHINGTON – U.S. defense contractor CACI International announced Feb. 6 it signed an agreement with the U.S. Army to...
- Advertisement -spot_img

Busek ramps up production for OneWeb constellation

SAN FRANCISCO – In-space propulsion specialist Busek revealed its role in helping OneWeb recover from the sudden loss of...

Must read

- Advertisement -spot_imgspot_imgspot_imgspot_img

You might also likeRELATED
Recommended to you